Knight Therapeutics, Inc.
http://www.gud-knight.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Knight Therapeutics, Inc.
RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager
Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.
Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout
Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Orphan Canada Inc.